AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06476990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy food box
Description: All participants received 12 weekly deliveries of food containing approximately $8 worth of shelf-stable food items purchased from a local food bank (beans, canned vegetables and no-sugar added fruit, shelf-stable dairy products, canned tuna, and whole grains) and $25 of fresh produce (5-7 items including leafy greens, peppers, potatoes, broccoli, carrots, zucchini, cauliflower, celery, cabbage, asparagus, apples, or strawberries). When seasonably available, fresh vegetables and fruit were sourced from local farmers via a local food hub. In addition to food, participants in the Food + CHW group also received 7 weekly virtual sessions with a CHW (four 90-minute ZOOM counseling sessions and three 30 to 60-minute check-in phone calls). CHW sessions included diabetes-appropriate cooking and nutrition education and personalized benefit enrollment and linkage to existing food access resources (for example SNAP, Double up Food Bucks, and Kansas Senior Farmers Market Vouchers).
Study NCT06476990 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy food box
Description: All participants received 12 weekly deliveries of food containing approximately $8 worth of shelf-stable food items purchased from a local food bank (beans, canned vegetables and no-sugar added fruit, shelf-stable dairy products, canned tuna, and whole grains) and $25 of fresh produce (5-7 items including leafy greens, peppers, potatoes, broccoli, carrots, zucchini, cauliflower, celery, cabbage, asparagus, apples, or strawberries). When seasonably available, fresh vegetables and fruit were sourced from local farmers via a local food hub. In addition to food, participants in the Food + CHW group also received 7 weekly virtual sessions with a CHW (four 90-minute ZOOM counseling sessions and three 30 to 60-minute check-in phone calls). CHW sessions included diabetes-appropriate cooking and nutrition education and personalized benefit enrollment and linkage to existing food access resources (for example SNAP, Double up Food Bucks, and Kansas Senior Farmers Market Vouchers).
Study NCT06283329 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: vocal cords echography
Description: Ultrasound assessments of the amplitude of the vocal cords movement were performed on a sagittal median section of the arytenoid cartilages with a 30° inclination using a Golf Head ultrasound probe at 3 different time points: before induction (T0), after extubation (T1), in recovery room 30 minutes after extubation(T2). We have defined H0, H1 and H2, the maximum course of the vocal cords measured respectively at T0, T1 and T2
Study NCT05255640 — intervention group
Intervention type: PROCEDURE
Intervention: operation of ischemia of the lower limbs
Description: The intervention technique is left to the judgment of the investigator to treat the ischemia
Study NCT06533982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval exercise session
Description: Physical activity session supervised and adapted on ergometer
Study NCT06533982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric neuromuscular exercise session
Description: Physical activity session supervised and adapted with a handgrip
Study NCT04914572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic rainforest mindful walking
Description: A two-kilometer trail curated by the National Parks Board, Singapore. The walk will be led by Mindfulness Practitioner who volunteered to be guides for this study.
Study NCT04914572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic rainforest walk
Description: A two-kilometer trail curated by the National Parks Board, Singapore. The walk will be led by volunteer guides recruited by the research team.
Study NCT04914572 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Campus Green walk
Description: A two-kilometer trail curated by the Office of Facility Management, NUS. The walk will be led by volunteer guides recruited by the research team.
Study NCT06254521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab combined with chemotherapy
Description: Drug: Oxaliplatin Oxaliplatin 130mg/m2 for chemotherapy on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for oxaliplatin-induced toxicity was implemented according to the report in BJC (2018) 118:1322-1328.~Drug: Capecitabine Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy from Day 1 to Day 14 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for capecitabine-induced toxicity was implemented according to the report in BJC (2018) 118:1322-1328.~Drug: Anti-PD-1 Monoclonal Antibody 200 mg on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The incidence of adverse events with Anti-PD-1 Monoclonal Antibodies is relatively low. The PD-1 monoclonal antibody (Tislelizumab) dose adjustment was implemented according to the prescribing information.~Other Names:~Tislelizumab~Procedure: Colectomy The specific surgical approach, whether it be laparoscopic
Study NCT05048771 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Patients will be surveyed through self-administered questionnaires and semidirected interviews with a psychologist
Study NCT05336682 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lesion Sterilization and Tissue Repair with radicular instrumentation
Description: Coronal and accessible radicular pulp tissue are extirpated using rotary files. After proper drying, the paste is placed in the cavity and the canals.
Study NCT05336682 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lesion Sterilization and Tissue Repair without radicular instrumentation
Description: Only the coronal pulp is removed, the pulpal floor is covered with triple antibiotic paste with propylene glycol mix.
Study NCT05336682 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional pulpectomy
Description: Pulp tissue extirpation is done. Biomechanical preparation is done using rotary files with frequent irrigation with Chlorhexidine. The canals are dried using sterile absorbent paper points followed by obturation by the paste of ZOE.
Study NCT06478784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: The experimental group (ACTIVE GROUP) will perform a circuit-based muscular strength program at high intensity three days per week for 10 weeks.~Each session will last approximately 45 minutes.~The Resistance training program will be supervised by staff from the Department of Health Sciences and Sports of the Miguel de Cervantes European University of Valladolid and will be carried out at the facilities of the Miguel de Cervantes European University of Valladolid.
Study NCT06478784 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low aerobic training
Description: Patients assigned to this group will perform exercise in static bicycle during 45 minutes three days a week, with a duration of 10 weeks.~This second group, despite performing the aerobic exercise, is considered control, since they will perform low-intensity aerobic exercise (50% of the maximum power developed in cycloergometer)~The Resistance training program will be supervised by staff from the Department of Health Sciences and Sports of the Miguel de Cervantes European University of Valladolid and will be carried out at the facilities of the Miguel de Cervantes European University of Valladolid.
Study NCT04977167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HG146
Description: HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.
Study NCT04977167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-(L)1 antibody
Description: PD-(L)1 Antibody is available as solution for infusion or lyophilized powder for reconstitution to be administered Q3W. It will be administered as an IV infusion for 30 minutes.
Study NCT06463015 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ultrasound-guided posterior tibial nerve pulsed radiofrequency
Description: The posterior tibial nerve (PTN) was identified with a 5-12 MHz linear ultrasonography (US) probe at the level of the medial malleolus, where it runs posterior to the posterior tibial artery. Using the in-plane technique, a 22-gauge, 10-cm radiofrequency cannula was inserted under US guidance and advanced until the tip was adjacent to the nerve. Pulse radiofrequency was applied at 42°C for 240 s with a pulse width of 20 ms
Study NCT06372093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picterus Jaundice Pro
Description: Picterus Jaundice Pro is a smartphone based screening tool for neonatal jaundice that takes images of the skin of the newborn chest where the Picterus Calibration Card is placed.
Study NCT04907240 — intervention group
Intervention type: DEVICE
Intervention: GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
Description: Intent to treat with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX) in the treatment of Peripheral Artery Disease as part of routine clinical practice.
Study NCT05359042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Patient Reported Outcomes platform
Description: The ePRO tool is developed by a third-party vendor, Conversa, and engages the patient in a chat-based interaction to assess patient symptoms and provide educational material.
Study NCT05359042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Related Quality of Life Surveys
Description: Surveys will be administered to participants
Study NCT05959447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camlipixant + Gemfibrozil
Description: Camlipixant will be administered alone as well as in co-administration with gemfibrozil
Study NCT05056350 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Quality of life questionnaires, work perception questionnaires, psychological distress questionnaire
Study NCT05056350 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: back to work coaching
Description: Back-to-work support program including an individual interview to identify patient needs and expectations, 7 coaching workshops (every 3 weeks +/- 15 days) and a final individual assessment post workshops
Study NCT05959447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate + camlipixant
Description: Dabigatran etexilate will be administered alone as well as in co-administration with camlipixant
Study NCT05388903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-2325a
Description: Subcutaneous injection (starting dose 30 mg)
Study NCT05388903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-2325a
Description: Intravenous infusion (starting dose 100 mg)
Study NCT05388903 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection
Study NCT05388903 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion
Study NCT05464992 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Additional CEST sequences during PET/MRI exam
Description: CE-Marked Advanced Technology Software Modules (ATSM) for Magnetic Resonance Imaging from General Electric Healthcare
Study NCT03435939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: 50 mg/day for 7 days followed by 100 mg/day for 12 weeks
Study NCT06146686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fanta AF blue rotary files 20 taper 4
Description: single rotary file Fanta AF blue rotary files 20 taper 4
Study NCT06146686 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fanta AF baby rotary files 20 , 25 , 30 taper 4
Description: multiple rotary files system Fanta AF baby rotary files 20 , 25 , 30 taper 4
Study NCT04288115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine
Description: Participants will be instructed to start the study medication the day after randomization. The study medication will be taken orally once a day.
Study NCT04288115 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be instructed to start the study medication the day after randomization. The study medication will be taken orally once a day.
Study NCT05512910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 200 mg minocycline orally or via nasogastric tube prior to successful reperfusion, followed by 100 mg every 12 hours times for a total of 5 days. If vomiting occurs within half an hour of the first dose, the clinician should assess the necessary of re-administering 100mg based on the severity of vomiting.
Study NCT05718882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Oral Product Plus VIC1911
Description: Lenvatinib: 8mg/day (≤ 60Kg), oral. VIC-1911:Groups were divided: 100mg bid（DL1, dose level 1）; 150mg bid（DL2）; 200mg bid(DL3), oral. 50mg bid is defined as DL(-1), 250mg bid is defined as DL(+1). A Bayesian Optimal Interval design schema will be followed to establish the maximum tolerated dose (MTD) of lenvatinib plus VIC-1911 combination and RP2D of VIC-1911 in HCC patients. The study would follow the Bayesian Optimal Interval Design with level size of 2 patients. The R package BOIN is available from CRAN.
Study NCT06375031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR011408 injection; HR011408 injection Placebo
Description: Medication regimen-A:~HR011408 injection, ante cibum; HR011408 injection Placebo , post cibum
Study NCT06375031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NovoRapid®; HR011408 injection Placebo
Description: Medication regimen-B:~NovoRapid®, ante cibum; HR011408 injection Placebo, post cibum
Study NCT06375031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR011408 injection Placebo; HR011408 injection
Description: Medication regimen-C:~HR011408 injection Placebo, ante cibum:~HR011408 injection, post cibum
Study NCT04593680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (F/TDF) and emtricitabine 200 mg/tenofovir alafenamide 25 mg (F/TAF)
Description: The first full PK measurement of MHT will be performed starting at week 4 and end at week 6 to assess the steady-state plasma PK of testosterone in the absence of PrEP. The second PK measurement of MHT will be performed starting at week 12 and end at week 14 to assess plasma PK of testosterone in the presence of both MHT and PrEP. The first full PK measurement of PrEP will be performed at week 12 to assess the steady-state plasma PK of FTC, TFV, and TAF; and intracellular PBMC FTC-TP and TFV-DP in the presence of both MHT and PrEP. The second measurement of PrEP will be performed at week 16 to assess plasma PK of FTC, TFV, and TAF; and intracellular PBMC FTC-TP and TFV-DP in the absence of MHT.
Study NCT06540573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory tests (examination)
Description: Laboratory tests (examination) to be performed include complete blood count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), liver function tests and kidney function tests; rheumatoid factor (RF), anti-cyclic citrullinated peptide antibody (anti-CCP antibody) and C-C Motif Chemokine Ligand 21 (CCL21).
Study NCT06540573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index
Description: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) This questionnaire is used to assess the health status of osteoarthritis patients introduced in 1988 (13). It is consisted of 33 items which evaluates the health and function of the patient from various aspects including: clinical symptoms (5 questions), severity of joint stiffness (2 questions), degree of pain (9 questions), and activity of daily living (17 questions).The test questions are scored on a scale of 0-4, which correspond to: None(0),Mild (1),Moderate (2),Severe(3),and Extreme (4).The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. Usually a sum of the scores for all three subscales gives a total WOMAC score, however there are other methods that have been used to combine scores.Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.
Study NCT06540573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The Disease Activity Score28 (DAS28)
Description: The Disease Activity Score (DAS) was created as a numerical tool for quantifying and assessing disease activity in rheumatoid arthritis (RA).The DAS28 (Disease Activity Score using 28 joint counts) was developed from the original DAS (Disease Activity Score).The DAS28 evaluates the disease activity by assessing the number of tender and swollen joints in a patient. Specifically, it considers 28 joints. The DAS28 also takes into account a blood marker of inflammation, typically the erythrocyte sedimentation rate (ESR) or the C-reactive protein (CRP) level.A patient with a DAS28 score of less than 2.6 is in remission; a score greater than or equal to 2.6 and less than 3.1 indicates low activity; a score greater than or equal to 3.1 and \<5.1 indicates moderate activity and a score 5.1 or more indicates high activity
Study NCT06540573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Patient global assessment (PGA)
Description: Patient global assessment (PGA) of disease activity will be reported by patients. PGA was developed in the late 1970s and was initially designed for the measurement of self-assessed pain in RA \[8\], although it has since been used to evaluate RA more globally. It is interesting to note that the way PGA is used in clinical practice covers, in fact, two very different concepts, one related to global health and the other to overall disease activity. They are both usually used under the heading of PGA without further specification for which is being assessed.
Study NCT05680168 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal electromagnetic stimulation
Description: Electromagnetic stimulation using Magneto STYM device, (Iskra medical d.o.o, Slovenia).
Study NCT05680168 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor exercises
Description: Pelvic floor muscle training in serial training sessions with our therapist
Study NCT06540573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Physician global assessment (PhGA)
Description: Physician global assessment (PhGA)of disease activity will be reported by the physician.The Physician Global Assessment (PhGA) of treatment response measures the overall response to treatment as assessed by the physician. The PhGA is a well accepted and commonly used scale for evaluating treatment response in clinical trials both in adults and children. PhGA is a simple instrument and the result is easily understood. However, assigning a score for PhGA requires a very detailed evaluation. To perform this assessment a physician/health care provider would use extensive data from every aspect of ICF.
Study NCT06540573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Health Assessment Questionnaire (HAQ)
Description: Functional impairment will be assessed with the Health Assessment Questionnaire (HAQ). It is a self-assessment tool used to measure functional ability in eight different areas: rising, dressing and grooming, hygiene, eating, walking, reach, grip, and activities of independent living. Each item or question is rated on a scale of 0 to 3, with 0 (normal/no difficulty), 1 (some difficulty), 2 (much difficulty), and 3 (unable to do). The 8 category scores are averaged, which represent an overall score from 0 (no disability) to 3 (completely disabled). If the questionnaire is slightly changed to reflect a certain disease, this does not affect the respective scoring.Scores 0-1 indicates mild to moderate disability, 1-2 indicates moderate to severe disability, and 2-3 indicates severe to very severe disability.
Study NCT05054023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Soulagel®
Description: topic gel
Study NCT05054023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arthrosyl®
Description: topic gel
Study NCT06540573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical disease activity index (CDAI)
Description: Clinical Disease Activity Index (CDAI) is a composite index (without acute-phase reactant) for assessing disease activity. CDAI is based on the simple summation of the count of swollen/tender joint count of 28 joints along with patient and physician global assessment on VAS (0-10 cm) Scale for estimating disease activity. The CDAI has range from 0 to 76
Study NCT06540573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The Simplified Disease Activity Index (SDAI)
Description: The Simplified Disease Activity Index for Rheumatoid Arthritis (SDAI) is a scoring system that has been validated in both research and clinical settings. It has been shown to have the highest sensitivity and specificity for predicting a physicians' decisions to change DMARD therapy when compared to other scores.Remission is defined as an SDAI of \<3.3, low disease activity as ≤11, moderate disease activity as ≤26 and high disease activity as >26. Response to therapy is considered moderate if SDAI decreases by ≥7 and major if decreases by ≥17
Study NCT06540573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Knee Radiography
Description: Knee osteoarthritis (gonarthrosis) will be evaluated using Kellgren-Lawrence (KL) staging on direct radiographs (anteroposterior and lateral views).Numerous variations of the Kellgren and Lawrence classification system have been used in research. Grade 0 (none): definite absence of x-ray changes of osteoarthritis. Grade 1 (doubtful): doubtful joint space narrowing and possible osteophytic lipping.Grade 2 (minimal): definite osteophytes and possible joint space narrowing. Grade 3 (moderate): moderate multiple osteophytes, definite narrowing of joint space, some sclerosis and possible deformity of bone ends Grade 4 (severe): large osteophytes, marked narrowing of joint space, severe sclerosis and definite deformity of bone ends. Osteoarthritis is deemed present at grade 2 although of minimal severity
Study NCT06221683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homoharringtonine
Description: 3mg/m2/day for weighing >10kg, 0.1mg/kg/day for weighing ≤10kg, d1-7, ivgtt, qd, more than 6 hours